Contact aspiration is comparable to stent retriever (SR) as frontline thrombectomy for patients with acute ischaemic stroke resulting from large vessel occlusion (LVO), according to the ASTER* trial presented at the recent International Stroke Conference (ISC 2017) held in Texas, Houston, US.
The phosphodiesterase 3 inhibitor cilostazol may prevent secondary stroke in individuals with a recent history of ischaemic stroke. However, there was a higher incidence of myocardial infarction in this group, according to findings of the PICASSO* study presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Initiating statin therapy within 24 hours of hospitalization for an acute ischaemic stroke did not appear to affect patient disability at 90 days poststroke, according to findings of the ASSORT* trial presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Intensive (triple) antiplatelet therapy does not affect the recurrence of ischaemic stroke or transient ischaemic attack (TIA) compared with guideline standard-of-care antiplatelet therapy, but increases the risk of bleeding, according to interim data from the TARDIS* trial presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas.
Resuming oral anticoagulation therapy after a lobar or nonlobar intracerebral haemorrhage (ICH) is associated with a lower risk of mortality and favourable functional outcome, according to results of a meta-analysis presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Individuals with cerebral venous thrombosis (CVT) have a lower likelihood of developing a pulmonary embolism compared with those with deep vein thrombosis (DVT), according to a study presented at the recent International Stroke Conference 2017 (ISC 2017) in Houston, Texas.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.